Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics Investigators. Henry NL, et al. Among authors: desta z. Breast Cancer Res Treat. 2009 Oct;117(3):571-5. doi: 10.1007/s10549-009-0309-1. Epub 2009 Jan 20. Breast Cancer Res Treat. 2009. PMID: 19153830 Free PMC article. Clinical Trial.
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL. Robarge JD, et al. Among authors: desta z. Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9. Breast Cancer Res Treat. 2017. PMID: 27943008 Free PMC article. Clinical Trial.
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM. Henry NL, et al. Among authors: desta z. J Clin Oncol. 2012 Mar 20;30(9):936-42. doi: 10.1200/JCO.2011.38.0261. Epub 2012 Feb 13. J Clin Oncol. 2012. PMID: 22331951 Free PMC article. Clinical Trial.
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL. Kadakia KC, et al. Among authors: desta z. Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23. Oncologist. 2016. PMID: 27009936 Free PMC article. Clinical Trial.
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy.
Robinson KM, Eum S, Desta Z, Tyndale RF, Gaedigk A, Crist RC, Haidar CE, Myers AL, Samer CF, Somogyi AA, Zubiaur P, Iwuchukwu OF, Whirl-Carrillo M, Klein TE, Caudle KE, Donnelly RS, Kharasch ED. Robinson KM, et al. Among authors: desta z. Clin Pharmacol Ther. 2024 Oct;116(4):932-938. doi: 10.1002/cpt.3338. Epub 2024 Jun 11. Clin Pharmacol Ther. 2024. PMID: 38863207
Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial.
Haddad TC, Suman VJ, Giridhar KV, Sideras K, Northfelt DW, Ernst BJ, O'Sullivan CC, Singh RJ, Desta Z, Peethambaram PP, Hobday TJ, Chumsri S, Leon-Ferre RA, Ruddy KJ, Yadav S, Taraba JL, Goodnature B, Goetz MP, Wang L, Ingle JN. Haddad TC, et al. Among authors: desta z. Clin Cancer Res. 2024 Aug 1;30(15):3147-3156. doi: 10.1158/1078-0432.CCR-24-0341. Clin Cancer Res. 2024. PMID: 38752717 Free PMC article. Clinical Trial.
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Mc Laughlin AM, et al. Clin Pharmacol Ther. 2024 Sep;116(3):690-702. doi: 10.1002/cpt.3238. Epub 2024 Mar 18. Clin Pharmacol Ther. 2024. PMID: 38494911
184 results